Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3

Teva Pharmaceutical has opened another front in its expansion into long-acting injectables, kicking off a phase 3 clinical trial of a prospect based on the same technology as its near-approval schizophrenia drug.